IMCR Immunocore Holdings plc
USHealthcareAs of 2026-10-08
Why IMCR matters now
Immunocore Holdings plc (IMCR) is a US stock in Healthcare. The latest InvestLog snapshot shows $29.09 with -1.09% on the session and $1.48B in market capitalization; recent performance reads 1-month -1.14% and YTD -17.60%.
The latest financial table shown here is Q1 2026, with revenue of $106.7M, net income of $13.0M, and EPS of $0.25. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.1%.
The latest indexable market news headline is "Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $46.50; recent insider activity includes Bell John Irving filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.69
P/S
3.77
EV/EBITDA
230.23
DCF Value
$-366.31
FCF Yield
-2.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.8%
Operating Margin
-7.6%
Net Margin
-4.9%
ROE
-4.8%
ROA
-1.8%
ROIC
-3.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $106.7M | $13.0M | $0.25 |
| Q4 2025 | $77.4M | $-22.3M | $-0.44 |
| FY 2025 | $297.6M | $-26.4M | $-0.53 |
| Q3 2025 | $103.7M | $785.0K | $0.02 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$46.50
Target (Median)
$46.50
Target Range
$38.00 - $55.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
GB
Exchange
—
Beta
0.75
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.